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Abstract
Mesenchymal stem cells (MSC) may have great potential for cell-based therapies of osteoarthritis. However, after
injection in the joint, only few cells adhere to defective articular cartilage and contribute to cartilage regenera-
tion. Little is known about the molecular mechanisms of MSC attachment to defective articular cartilage. Here,
we developed an ex vivo attachment system, using rat osteochondral explants with artificially created full-
thickness cartilage defects in combination with genetically labeled MSC isolated from bone marrow of human pla-
cental alkaline phosphatase transgenic rats. Binding of MSC to full-thickness cartilage lesions was improved by
serum, but not hyaluronic acid, and was dependent on the presence of divalent cations. Additional in vitro tests
showed that rat MSC attach, in a divalent cation-dependent manner, to collagen I, collagen II, and fibronectin,
but not to collagen XXII or cartilage oligomeric matrix protein (COMP). RGD peptides partially blocked the ad-
hesion of MSC to fibronectin in vitro and to cartilage lesions ex vivo. Furthermore, the attachment of MSC to col-
lagen I and II in vitro and to cartilage lesions ex vivo was almost completely abolished in the presence of a b1
integrin blocking antibody. In conclusion, our data suggest that attachment of MSC to ex vivo full-thickness car-
tilage lesions is almost entirely b1 integrin-mediated, whereby both RGD- and collagen-binding integrins are in-
volved. These findings suggest a key role of integrins during MSC attachment to defective cartilage and may
pave the way for improved MSC-based therapies in the future.
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Introduction
Cell therapies or cell-based gene therapies with adult
multipotent mesenchymal stem cells (MSC) may have
a large impact on the treatment of many diseases of
various organ systems in the future.1 One of the typical
diseases in which MSC-based therapies may hold great
promise is osteoarthritis (OA). OA is the most com-
mon age-related form of arthritis with prevalence for
the knee and hip joint. The initiation of the disease is
triggered by genetic disposition, single major trauma,
a series of microtraumas, or strenuous exercise.2 The
few differentiated chondrocytes within the articular car-
tilage have only minimal regeneration potential,3 lead-
ing to a poor prognosis for patients suffering fromOA.4
Murphy et al. demonstrated that the intra-articular in-
jection of autologous bone marrow-derived MSC in a
goat model of OA stimulated the regeneration of
meniscal tissue and retarded progressive joint destruc-
tion.5 Since then, other studies investigating cartilage
regeneration using MSC also reported successful and
promising results in various model systems.6–10 How-
ever, only a small fraction of injected cells adhere to
damaged cartilage and therefore contribute to tissue
regeneration.11 In addition, it is currently a matter of
debate whether the beneficial effects of MSC therapy
is due to a progenitor or a nonprogenitor function of
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the injected cells.12 Therefore, the clinical potential of
MSC-based therapy of OA is currently unclear.
MSC are a cell population of undifferentiated cells
isolated from adult bone marrow or other tissues with
the capacity to differentiate into mesodermal lineages
such as bone, cartilage, muscle, or fat tissue. They can
be isolated and expanded with low effort and can be
differentiated into multiple cell lineages under certain
culture conditions. Cultured MSC are positive for the
surface markers CD44, CD73, CD90, CD105, CD106,
CD120a, and CD124.13 Beside those, they also express
various integrin subunits such as a1, a2, a3, a4, a5, a6,
a7, a10, aV, aIIb, b1, b3, b4, and b5.13–15 Integrins are
thought to play a pivotal role in adhesion of MSC to ex-
tracellular matrix (ECM) proteins and biocompatible
polymers.16–18 The noncovalent binding of an a- and
a b-subunit builds a full integrin, which is activated,
and stretched in length, by binding to intracellular or
extracellular proteins that drive the signaling to the
ECM or to the cell.19–21 The integrin family consists
of five different groups depending on their ligand
binding. For example, collagen-binding integrins
prefer the binding to the collagenous triple helix,
whereas RGD-binding integrins, the largest subgroup,
bind exclusively the amino acid motif Arg-Gly-Asp.22
Integrins mediate processes such as adhesion, migra-
tion, proliferation, cytoskeleton organization, and
survival.20
In order to function as progenitors for cartilage re-
generation intra-articularly injected MSC need to at-
tach to articular cartilage lesions. Articular cartilage
can be divided into distinct zones depending on the or-
ganization and shape of the embedded chondrocytes.
The superficial zone, the outermost zone of the articu-
lar cartilage harbors only few differentiated chondro-
cytes with a flattened cell shape that are organized in
parallel and embedded in a tight ECM.3 The cartilage
ECM consists of high amounts of collagens and pro-
teoglycans that build large aggregates embedded into
the collagen network.23 The predominant collagen in
articular cartilage is collagen II that forms fibrils with
integrated collagen IX and XI.24 Noncollagenous pro-
teins such as COMP (cartilage oligomeric matrix pro-
tein), matrilin-3, biglycan, decorin, and aggrecan, as
well as the glycosaminoglycan hyaluronan, and other
factors are needed to interconnect the different networks,
thereby strengthening the ECM in articular cartilage.25
Cartilage defects result in the degradation of the ECM
followed by inflammatory processes, apoptosis of chon-
drocytes, and subsequent loss of articular cartilage and
sclerosis of the subchondral bone in combination with
osteophyte formation, ultimately leading to OA.
Currently, only little is known about the molecular
mechanisms involved in MSC adhesion to cartilage le-
sions. Here, we set out to characterize the attachment
of rat MSC to full-thickness cartilage lesions and to
ECM components in more detail, using a combination
of ex vivo and in vitro systems. To this end, we first de-
veloped an ex vivo attachment system, using rat osteo-
chondral explants with full-thickness cartilage defects
in combination with genetically labeled, bone mar-
row-derived rat MSC. To identify the attached MSC
on the tibial explants, we used human placental alkaline
phosphatase (hPLAP) expressing MSC, which harbor
the same characteristics as wild-type cells and are
easy to track by histochemical staining.26,27 hPLAP is
a heat-stable marker enzyme that retains its enzymatic
activity after paraffin and plastic embedding.26 Next,
we investigated the effect of adjuvants such as hyalur-
onic acid, serum, plasma, and divalent cations on
MSC attachment to cartilage lesions. Finally, we ana-
lyzed the attachment of MSC to individual ECM pro-
teins in vitro. MSC were able to bind to bone and
cartilage ECM proteins via b1 integrins of the collagen-
binding and RGD-binding integrin family. These findings
suggest a key role of integrins during MSC attachment
to defective cartilage and may pave the way for im-
proved cell-based therapies with MSC in the future.
Materials and Methods
Animals
All animal experiments were approved by the ethics
committees of the University of Veterinary Medicine
and of the local government authorities. Wild-type
and hemizygous female R26-hPLAP-tg inbred Fischer
344 rats originally generated by Kisseberth and co-
workers,28 ubiquitously expressing the marker gene
hPLAP, were genotyped by enzymatic histochemistry
using a drop of tail blood.28,29 Rats were housed in
groups of 2–6 at 24C and a 12 h/12 h light/dark
cycle with free access to tap water and a standard rat
diet (Ssniff).
MSC isolation
Bone marrow-derived MSC were isolated from wild-
type and hPLAP-tg female rats at the age of 3–6
weeks according to the protocol described by Balmayor
et al.27 In brief, long bones (femur, tibia, and humerus)
were defleshed, cut at the epiphysis, and subsequently
digested with 2.5mg/mL collagenase type II (Invitrogen)
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for 2 h. The bonemarrow was flushed out with complete
medium containing Eagle’s minimum essential me-
dium (MEM; PAA, GE Healthcare), 10% fetal bovine
serum (FBS; PAA, GE Healthcare), and 1% penicillin/
streptomycin (PAA, GE Healthcare), and centrifuged.
With the help of a Ficoll gradient centrifugation
(Ficoll-Paque; GE Healthcare) the mononuclear cell
fraction was collected, washed, and seeded in cell cul-
ture flasks (TPP; Trasadingen). After 24 h, the medium
was changed and the cells were grown until 80% con-
fluence. Cells were passaged up to passage 4. During
cultivation, the medium was changed twice a week
and cells were kept at 37C with 5% CO2 and 3% O2.
Ex vivo attachment assay with osteochondral explants
Tibiae from wild-type rats at the age of 5–7 months
were isolated, cleaned from surrounding soft tissue
without damaging the articular cartilage, and kept in
PBS (without Ca2+ and Mg2+ ; PAA, GE Healthcare).
Full-thickness defects with a diameter of 1mm were
created on the lateral and medial compartment of the
tibia’s articular cartilage with the help of a biopsy
punch. Some tibia plateaus were left intact as a control.
The tibia plateau was broken at the epiphysis, and the
resulting osteochondral explants were separated into
the medial and lateral compartment with a scalpel.
Each explant was placed into a well of a 96-well plate
(TPP; Trasadingen), washed, and kept in complete me-
dium overnight at 37C, 5% CO2, and 3% O2. The ex-
plants were placed into a new 96-well plate and washed
30–60min with PBS. Single-cell suspensions of 1 · 104
hPLAP-tg MSC per explant at passage 1–4 were incu-
bated on upright-positioned explants for 55min unless
otherwise indicated at 37C, 5% CO2, and 3% O2 in
physiological saline (Fresenius) alone or supplemented
with rat serum (native, isolated whole blood of wild-
type rats) or bovine serum (FBS; PAA, GE Healthcare),
plasma (native, isolated from whole blood of wild-type
rats, using EDTA as anticoagulant), bone marrow
plasma (native, isolated from wild-type rats), hyalur-
onic acid (sodium salt from Streptococcus equi;
Sigma), divalent cations (MgCl2, CaCl2, ZnCl2, and
MnCl2; Sigma), or 10mM EDTA (Sigma).
For blocking and competition assays, saline supple-
mented with 50% serum and b1 integrin blocking an-
tibody (clone Ha2/5; BD Biosciences), hamster IgM
k1 isotype control (BD Biosciences), linear RGD pep-
tide (GRGDNP), or linear RGD control peptide
(GRADSP) (both from Enzo Life Sciences) were used.
The explants were washed twice with PBS to remove
nonadherent cells. Adherent cells were fixed with ice-
cold acetone–methanol (30:70 v/v) for 3min at 20C.
After a washing step, the explants were placed in
1.5mL tubes containing 1mL PBS and incubated at
72C and 200 rpm for 90min to inactivate endogenous
alkaline phosphatases. Subsequently, explants with
attached cells were stained for heat-stable hPLAP
by using TNM buffer (100mM Tris-HCl, pH 9.5,
100mM NaCl, 5mM MgCl2) containing 0.175mg/
mL 3-bromo-4-chloro-3-indolyl phosphate (BCIP;
Sigma) and 0.45 ng/mL nitrotetrazolium blue chloride
(NBT; Sigma) for 3 h at room temperature (RT). The
staining solution was replaced by PBS, and the explants
were photographed under a stereomicroscope (Stemi
SV6; Zeiss).
The obtained pictures were formatted to a size of
35 cm· 35 cm and a cutout of 10 cm· 15 cm with the
defect in its center taken. The cutouts were analyzed
with ImageJ software, and the area of attached and
stained MSC was expressed as percent of the defect
area. All measurements were done in triplicate with
explants from three different animals per group, and
repeated independently at least three times on dif-
ferent days with different MSC batches. Identically
treated cell-free explants were used as additional nega-
tive controls.
Histochemistry of cryosections
hPLAP-stained and quantified osteochondral explants
were fixed in 70% ethanol for 48 h and decalcified
with 0.5M EDTA, pH 8.0, for 4 weeks at 4C. There-
after, the explants were embedded in TissueTek
(Sakura Finetek), shock-frozen in liquid N2, and kept
at 80C until sectioning. Eleven-micrometer-thick
cryosections were transferred to 3-aminopropyltrie-
thoxy-silane (APES; Sigma)-pretreated slides. For
hPLAP staining, sections were fixed with acetone–
methanol (30:70 v/v) for 3min at 20C. As the decal-
cification procedure inactivates the hPLAP marker
gene, reactivation had to be performed as described
earlier.30 Therefore, all alkaline phosphatases were
reactivated with 1% MgCl2 in 100mM Tris-maleate
buffer, pH 9.2, overnight in darkness. To inactivate en-
dogenous alkaline phosphatases, sections were subse-
quently incubated at 65C for 35min. The staining
was carried out as described in detail before.29 Nuclear
fast red (Sigma) was used as counterstain. For Alcian
blue-PAS (periodic acid-Schiff) staining, a PAS stain-
ing kit (Merck) was used according to manufacturer’s
instructions after sections were fixed with 4% PFA
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(paraformaldehyde) for 5min at RT. Pictures of the
stained sections were taken with a microscope (Axio-
skop 2; Zeiss).
Immunofluorescence staining of cryosections
Anti-integrin immunofluorescence staining was per-
formed on cryosections of hPLAP-prestained osteo-
chondral explants as described previously.31,32 In
brief, sections were fixed with ice-cold acetone for
2min at 20C and blocked with 5% normal goat
serum (Vector Laboratories) in PBS supplemented
with 0.2% Tween-20 for 30min at RT. Cryosections
were stained overnight at 4C for collagen I (rabbit
polyclonal; Rockland Immunochemicals), collagen II
(rabbit polyclonal; Rockland Immunochemicals), a1
integrin (hamster clone Ha31/8; BD Biosciences), a2
integrin (mix of three rat clones; Emfret), and a5 integ-
rin (rabbit polyclonal; Santa Cruz Biotechnology), or a
combination of a2 integrin and collagen I or collagen II
for co-immunofluorescence staining, followed by incu-
bation with FITC-conjugated goat anti-rabbit (Sigma),
Alexa 488-conjugated goat anti-rat (Molecular Probes),
Texas Red-conjugated goat anti-hamster (Vector Labo-
ratories), and Cy3-conjugated goat anti-rabbit ( Jackson
ImmunoResearch), either single or in mixture, for 1 h at
RT. Stained sections were analyzed and pictures were
taken with a microscope (Axioskop 2; Zeiss).
In vitro cell attachment assay
In vitro cell attachment assays were carried out accord-
ing to Eble et al.33 In brief, the following proteins were
immobilized overnight at 4C onto 96-well plates
(Nunc): collagen I (bovine; Sigma), collagen II (rat, na-
tive extracted from trachea described by Dodge and
Poole34), collagen XXII (human, gift of Manuel Koch,
University of Cologne32), fibronectin (human; Sigma),
COMP (rat, recombinant protein according to Hansen
et al.35), and bovine serum albumin (BSA; Sigma). Free
binding sites were blocked with 1% BSA in PBS for 3–
4 h at 4C. Single-cell suspensions of wild-type or
hPLAP-tg MSC at passage 1–4 were incubated for
55min at 37C, 5% CO2, and 3% O2 in physiological
saline, or MEM alone or in combination with different
concentrations of divalent cations (MgCl2, CaCl2,
ZnCl2, and MnCl2), 1mM MnCl2 and 2mM MgCl2,
or 10mM EDTA at an average density of 6· 104
cells/mL. For blocking and competition assays, MEM
supplemented with 1mM MnCl2 and 2mM MgCl2
and b1 integrin blocking antibody, hamster IgM k1 iso-
type control, RGD peptide, and RGD control pep-
tide were used. Nonadherent cells were removed by
washing with PBS and adherent cells fixed with 1% glu-
taraldehyde (Sigma) in PBS for 15min at RT. After
staining with 0.1% (w/v), crystal violet cells were
lysed with 0.2% Triton X-100 (Sigma). The amount
of released dye was determined by measuring the ab-
sorption at 570 nm using a microplate reader (EnSpire;
Perkin Elmer). All measurements were done in trip-
licate and repeated independently at least three
times. Identically treated PBS-coated wells were used
as blanks.
Statistical analysis
All obtained values are reported as mean – standard de-
viation. All statistical analyses were performed with
IBM SPSS Statistics 20 (IBM). Normal distribution of
the data was analyzed by the Kolmogorov–Smirnov
test. Student’s t-test for two independent samples and
one-way ANOVA followed by Student–Newman–
Keuls (SNK) post hoc test for more than two groups
were used to determine differences of indicated groups;
p-values < 0.05 were considered significant.
Results
Establishment of an ex vivo system to study MSC
attachment to cartilage lesions
The attachment potential of cells can be analyzed in
in vitro cell attachment assays. However, one disadvan-
tage of these in vitro systems is that the coating with
specific proteins only partially mimics the complex
composition of a specific tissue. Therefore, we devel-
oped an ex vivo attachment system in native articular
cartilage. To analyze the attachment of hPLAP-tg
MSC to defective cartilage in osteochondral explants
from wild-type rats, we created a full-thickness defect
on the lateral and on the medial compartment of the
tibia’s articular cartilage, and used the defects as surface
for the MSC attachment. To characterize the matrix
components exposed in the defects, we performed
alcian blue-PAS staining of cryosections.
Figure 1A shows that hyaline cartilage, calcified car-
tilage, as well as subchondral bone were exposed in the
full-thickness defects. Single-cell suspensions of donor
MSC isolated from hPLAP-tg rats were allowed to at-
tach to the osteochondral explants. The area covered
with hPLAP-tg MSC within the defect was quantified
after washing, fixation, and histochemical staining of
the hPLAP-tg cells. We first sought to optimize the
seeding cell density in this osteochondral explants
(Fig. 1B,C). When seeding 104 cells per explant, we
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FIG. 1. Establishment of an ex vivo attachment system. (A) Alcian blue-PAS staining of cryosections of
osteochondral explants with a full-thickness defect. Articular cartilage is stained purple, subchondral bone is
stained magenta, and proteoglycans and nuclei are stained blue. (B, C) Screen for optimal cell number. Ex vivo
osteochondral explants from wild-type Fischer 344 rats were used to analyze the attachment of human
placental alkaline phosphatase (hPLAP)-tg mesenchymal stem cells (MSC) to cartilage lesions. After attachment,
the cells were fixed, and histochemically stained for hPLAP after heat inactivation of endogenous alkaline
phosphatases. The stained area within the defect, corresponding to the attached cells, was quantified with the
help of ImageJ software. Indicated numbers of cells suspended in 2% rat serum were allowed to attach for 24 h.
Dashed circle in (B) indicates the full-thickness defect on the osteochondral explant. *p< 0.05 vs. 104 cells/
explant by one-way ANOVA followed by Student–Newman–Keuls (SNK) test. (D) Screen for optimal attachment
time. An amount of 104 hPLAP-tg MSC per explant suspended in 2% rat serum were allowed to attach for the
indicated time to the osteochondral explants. *p< 0.05 vs. 1 h incubation time by one-way ANOVA followed by
SNK test. (E) Testing different vehicles for MSC attachment to full-thickness cartilage defects. An amount of 104
MSC suspended in saline alone or saline supplemented with 10% rat serum, plasma, bone marrow plasma, or
hyaluronic acid were allowed to attach for 55min. *p < 0.05 vs. saline by one-way ANOVA followed by SNK test.
(F, G) Influence of increasing concentrations of bovine serum to MSC attachment. An amount of 104 MSC
suspended in saline supplemented with 0–50% serum were allowed to attach to osteochondral explants for
55min. Attachment to intact and defective surfaces was quantified on separate explants. Dashed circle in (F)
indicates the full-thickness defect on the osteochondral explant. *p < 0.05 and **p< 0.001 by Student’s t-test.
Data represent mean values– SD (n‡ 3). All experiments were performed in triplicate and in at least three
independent experiments. (H) Histochemical hPLAP/nuclear fast red staining of osteochondral explants.
hPLAP-tg MSC (arrows) were stained in dark violet on cryosections of intact and defective osteochondral
explants. Cartilage is stained orange-red and subchondral bone is stained red. Scale bar = 100 lm.
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reached an optimal readout with single cells being dis-
tributed homogenously over the defect area, and room
for quantification of increases and decreases in cell at-
tachment. The initial attachment of cells is followed by
processes such as spreading, proliferation, and/or mi-
gration.36 Therefore, we next determined the optimal
adhesion time for our ex vivo attachment assay. Most
of the seeded hPLAP-tg MSC attached within 0.5–1 h
to the defective cartilage (Fig. 1D). After 2 h of incuba-
tion, only a small further increase in the covered
area could be observed. It is likely that this fur-
ther increase after prolonged incubation for up to
2 h was caused by spreading during which the cells
get flattened and increase their contact surface.
Taken together, we established a novel ex vivo sys-
tem based on the attachment of hPLAP-tg MSC to
cartilage lesions on osteochondral explants. This sys-
tem is similar to the classic in vitro attachment as-
say but with the advantage of using native tissue as
attachment surface.
Serum and divalent cations facilitate MSC adhesion
to defective cartilage
Many studies describe the use of serum as vehicle for
MSC application in cell-based therapies.6,10 In addi-
tion, the use of hyaluronic acid is described to have a
positive effect on MSC attachment after intra-articular
injection.5,8 We therefore tested several vehicles suit-
able for increasing MSC adhesion to cartilage lesions
in our osteochondral explant system. Administration
of hPLAP-tg MSC in 10% rat serum enhanced the at-
tachment compared to saline, as well as 10% of plasma
or bone marrow plasma (Fig. 1E). The use of 10% hya-
luronic acid also increased MSC attachment, but to
a lower extent than serum, plasma, or bone marrow
plasma. A more detailed analysis showed that the
addition of serum dose-dependently increased the
MSC-covered area on both the intact and the defective
cartilage, but that adhesion to the defective cartilage
was significantly higher at all serum concentrations at
the used seeding density of 104 cells per explant (Fig.
1F,G). For the quantification of MSC attachment on in-
tact explants, independent explants without defect were
used. It is interesting to note in Figure 1F that on ex-
plants with a defect, more MSC attached to the sur-
rounding intact cartilage surface compared to intact
explants without a defect. This suggests that already
minor damage (also seen in Fig. 1H, middle panel,
left arrow) of the cartilage surface in the surroundings
of the full-thickness defect induced by handling and
cleaning of the sample facilitates attachment of MSC.
Histological staining of hPLAP-tg MSC in cryosections
FIG. 1. (Continued).
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confirmed the attachment of these cells in and in the
surroundings of the full-thickness defects in the osteo-
chondral explants (Fig. 1H). These results show that
serum enhances MSC adhesion to cartilage lesions.
Earlier studies reported positive effects of mag-
nesium and calcium on cell attachment.37–39 We
therefore tested the ability of divalent cations such as
magnesium, calcium, zinc, and manganese to improve
the adhesion of MSC to defective cartilage in our
system. Magnesium caused a dose-dependent increase
in the MSC-covered area up to 10mM concentrations,
whereas calcium and manganese showed only a non-
significant enhancement at 1 and 2.5mM (Fig. 2A).
Surprisingly, zinc, which is known to have an impact
FIG. 2. Divalent cations are necessary for ex vivo MSC attachment to cartilage lesions. (A, B) Influence of
different concentrations (A) and combinations (B) of divalent cations on MSC attachment to cartilage defects.
MSC suspended in saline were preincubated with the indicated divalent cation concentrations or with 10mM
EDTA, and allowed to attach to osteochondral explants for 55min. Only attachment to the cartilage defects was
quantified. Data represent mean values – SD (n ‡ 3). All experiments were performed in triplicate and in at least
three independent experiments. Note that for Mn2+ , only the 1mM concentration and for Zn2+ , only the 1mM
and 2.5mM concentrations were tested. *p < 0.05 vs. saline by one-way ANOVA followed by SNK test. (C)
Horizontal images and cryosections of hPLAP-stained osteochondral explants seeded with hPLAP-tg MSC in
Mg2+ and Ca2+ -supplemented saline or EDTA. Left panels show representative horizontal images of hPLAP-
stained osteochondral explants used for quantification in (B). Dashed circle indicates the full-thickness defect
on the osteochondral explant. In hPLAP-stained cryosections, attached hPLAP-tg MSC (arrows) were found in
the defects after incubation in saline supplemented with 1mM Mg2 + and 2.5mM Ca2 + (left), but not when
suspended in 10mM EDTA (right). Nuclear fast red was used as counterstaining. Cartilage is stained orange-red
and subchondral bone is stained red. Scale bar = 100 lm.
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on the binding affinity and conformation of ECM pro-
teins in cartilage,40 had no effect on MSC attachment
compared with saline as vehicle. When using combina-
tions of divalent cations as present in MEM medium, a
nearly 2-fold increase in MSC adhesion was observed
with a near-physiological combination of 1mM mag-
nesium and 2.5mM calcium as compared to single
components and other ion combinations (Fig. 2B).
In addition to saline, the divalent cation chelator
EDTA21 was used as a negative control. Horizontal im-
ages of hPLAP-stained explants and histological stain-
ing of attached MSC confirmed these findings (Fig.
2C). In conclusion, we found that serum and the diva-
lent cations magnesium and calcium improved the ad-
hesion of MSC to full-thickness cartilage defects in our
explant system.
Collagen I, collagen II, and fibronectin mediate MSC
attachment in vitro
To evaluate the specific matrix components mediating
MSC attachment to full-thickness cartilage lesions, we
performed in vitro cell attachment assays with promi-
nent ECM proteins of cartilage and bone. In a one-
point measurement to screen for putative interaction
partners, we used the following ECM proteins: collagen
I, present in bone, and the major cartilage proteins
collagen II, collagen XXII, COMP, and fibronectin,
which is known to be expressed in bone and cartilage.
Only collagen I, collagen II, and fibronectin mediated
MSC attachment. MSC adhered neither to collagen
XXII, a prominent marker of the articular cartilage sur-
face,31 nor to COMP (Fig. 3A). Collagen I, collagen II,
and fibronectin mediated the MSC attachment in a
concentration-dependent and saturable manner in the
presence of the divalent cations manganese and magne-
sium (Fig. 3B). MSC adhesion to collagen I, collagen II,
and fibronectin was inhibited completely by 10mM
EDTA (Fig. 3B).
To compare ex vivo and in vitro experiments, we
tested several divalent cations for their ability to influ-
ence MSC attachment in vitro. In general, all tested cat-
ions had their strongest positive influence on MSC
adhesion at physiological concentrations of 1 or
2.5mM. Zinc of 1mM had the most pronounced effect
on MSC adhesion to collagen II (Fig. 3D). Zinc is pres-
ent at a concentration of about 1mM in cartilage and
has the ability to change the conformation of ECM
proteins such as collagen II, collagen IX, and COMP,
and influences their binding ability to each other.40
Interestingly, calcium had a negative effect on the ad-
hesion to collagen I and no effect on the adhesion to
collagen II.
In addition, we tested combinations of divalent cat-
ions, similar to the above-mentioned ex vivo experi-
ments. Combinations of 1mM manganese with 2mM
magnesium and of 2.5mM magnesium with 1mM cal-
cium had the most positive effects on MSC attachment
to collagen I (Fig. 3E). The adhesion of MSC to collagen
II was significantly increased when using 1mMmanga-
nese with 2mM magnesium, or 2.5mM magnesium
with 1mM calcium (Fig. 3F). In agreement with the ex-
periments shown in Figures 2B and 3B, the attachment
of MSC to collagen I and collagen II was almost com-
pletely inhibited in the presence of 10mM EDTA (Fig.
3E,F). Collectively, these data demonstrate that MSC
are able to attach, in a divalent cation-dependent man-
ner, to the ECM proteins collagen I, collagen II, and fi-
bronectin, all present in bone and cartilage tissue.
b1 integrins mediate MSC attachment
in vitro and ex vivo
Because the MSC attachment was almost completely
abolished in the presence of EDTA, we hypothesized
that integrins may be involved in the adhesion of
MSC to matrix proteins exposed in cartilage lesions.
MSC are known to express the b1 integrin subunit
on their cell surface,13,14 which is also used as a marker
to identify MSC after isolation. Furthermore, they ex-
press the subunits a1, a2, and a10, belonging to the
family of collagen-binding integrins, and the subunits
a5 and aV belonging to the RGD-binding integrins.14,15
Thus, MSC express both collagen- and RGD-binding
integrins.
To identify the integrins involved in MSC adhesion
to ECM proteins and cartilage lesions, we performed
competition and inhibition assays. We first performed
competition experiments with RGD peptide in the
in vitro attachment system. Only the MSC attachment
to fibronectin could be inhibited by about 60% by the
RGD peptide (Fig. 4A). The attachment to collagen I
and collagen II was unaffected by the RGD peptide
(Fig. 4A). An RGD control peptide served as a negative
control. Blocking assays with a monoclonal b1 integrin
blocking antibody revealed that the b1 integrin subunit
was essential for binding of MSC to collagen I and col-
lagen II. If the b1 integrin subunit was blocked, MSC
could no longer adhere to collagen I and collagen II,
whereas addition of an isotype control antibody had
no influence on the attachment of MSC (Fig. 4B). In
contrast, attachment of MSC to fibronectin was not
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FIG. 3. In vitro attachment of MSC to extracellular matrix (ECM) proteins of bone and cartilage. (A) Screen of
MSC adhesion to abundant ECM proteins. An amount of 20 lg/mL of protein was immobilized at 4C overnight.
(B) Adhesion of MSC to collagen I, collagen II, and fibronectin. Serial dilutions of collagen I (Col I, 0.3–20 lg/mL),
collagen II (Col II, 0.02–20 lg/mL), and fibronectin (FN, 0.3–20 lg/mL) were immobilized at 4C overnight. In (A)
and (B), MSC suspended in MEM were allowed to attach to the substrate for 55min in the presence of Mn2 +
and Mg2+ or EDTA, followed by crystal violet staining. Relative attachment is presented as DE, measured
extinction minus nonspecific attachment to PBS-pretreated wells. Data represent mean values – SD. (n = 3). At
least three independent assays were performed for all experiments. Bovine serum albumin (BSA) was used as
negative control. (C, D) Influence of different concentrations of divalent cations on MSC attachment to collagen
I and II. An amount of 2.5 lg/mL collagen I (C) or collagen II (D) was immobilized onto 96-well plates overnight.
(E, F) Influence of combinations of divalent cations on the attachment of MSC. An amount of 2.5 lg/mL
collagen I (E) or collagen II (F) was immobilized overnight. In (C)–(F), MSC suspended in saline were
preincubated with the indicated divalent cation concentrations or with 10mM EDTA, and were allowed to
attach to the substrate for 55min. Relative attachment is presented as relative DE, normalized to the
attachment (DE) of MSC suspended in saline. Data are mean – SD (n = 3). At least three independent assays
were performed for all experiments. Note that for Mn2 + , only the 1mM concentration was measured. *p < 0.05
vs. saline by one-way ANOVA followed by SNK test.
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FIG. 4. Adhesion of MSC in vitro and ex vivo is b1 integrin dependent. (A, B) Influence of RGD peptides and a
b1 integrin blocking antibody on MSC attachment to ECM proteins in vitro. An amount of 2.5 lg/mL of collagen
I (Col I), collagen II (Col II), and fibronectin (FN) was immobilized at 4C overnight. MSC were suspended in MEM
containing Mn2+ and Mg2 + , supplemented with the indicated concentrations of RGD peptide, RGD control
peptide, b1 integrin blocking antibody, or IgM k1 isotype control, and were allowed to attach for 55min to the
substrate. Attachment was quantified as DE, measured extinction minus nonspecific attachment to PBS-
pretreated wells, and is given as % inhibition. Data represent mean values – SD (n = 3). At least three
independent assays were performed for all experiments. (C, D) Influence of RGD peptides and a b1 integrin
blocking antibody on MSC attachment to full-thickness cartilage lesions ex vivo. MSC were suspended in saline
containing 50% bovine serum and supplemented with the indicated concentrations of RGD peptide, RGD
control peptide, b1 integrin blocking antibody, or IgM k1 isotype control. MSC were allowed to attach for
55min to the osteochondral explants. Only attachment to the cartilage defects was quantified. Data represent
mean values – SD (n ‡ 3). All experiments were performed in triplicate and in at least three independent
experiments. *p < 0.05 vs. 50% bovine serum without blocking supplement by one-way ANOVA followed by
SNK test.
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completely blocked by the b1 integrin blocking anti-
body (Fig. 4B). These results demonstrate that MSC
bind to fibronectin via RGD-binding integrins, and to
collagen I and collagen II via collagen-binding integrins.
To confirm the role of RGD- and collagen-binding
integrins in MSC attachment to full-thickness cartilage
lesions in the more complex ex vivo situation, we per-
formed competition and blocking studies in the osteo-
chondral explant system. The RGD peptide was able to
compete for about 50% of the attachment of MSC to
full-thickness cartilage lesions, whereas the RGD con-
trol peptide had no influence (Fig. 4C). Blocking stud-
ies with a b1 integrin blocking antibody demonstrated
a dose-dependent inhibition of the MSC attachment to
defective cartilage with a maximum inhibition of about
90% at 40lg/mL antibody concentration, whereas an
isotype control antibody had no influence on MSC at-
tachment (Fig. 4D). These results fully corroborate our
in vitro findings and clearly show that attachment of
MSC to full-thickness cartilage lesions in our ex vivo
system is almost entirely b1 integrin-mediated, whereby
both RGD- and collagen-binding integrins are involved.
To identify potential integrin a-subunits involved in
the adhesion of MSC to full-thickness cartilage defects,
we performed immunofluorescence analyses (Fig. 5).
Staining of cryosections of intact osteochondral ex-
plants for collagen I and II confirmed the specificity
of the used antibodies. The anti-collagen I antibody
clearly stained the bone tissue, whereas collagen II
was expressed exclusively in the articular cartilage
and calcified cartilage of the epiphysis in intact osteo-
chondral explants (Fig. 5A). The collagen I and II stain-
ing pattern was similar to the distribution of bone and
cartilage tissue as evidenced by alcian blue-PAS stain-
ing (Fig. 5B). Co-immunofluorescence analysis for a2
integrin and collagen I and II demonstrated distinct
zones of adjacent expression of a2 integrin and colla-
gen I and II in areas where MSC attached to subchon-
dral bone or hyaline cartilage, respectively (Fig. 5C and
D). In contrast, expression of a1 (Fig. 5E) or a5 integrin
(Fig. 5F) was not observed in the defects. Taken to-
gether, our findings suggest that a2b1 integrin may
be one of the key mediators of MSC attachment to
bone and cartilage in full-thickness cartilage lesions.
Discussion
The key findings in our study were (1) that serum im-
proves MSC attachment to cartilage lesions, (2) that
divalent cations are essential for binding of MSC to
full-thickness cartilage lesions as well as for MSC bind-
ing to collagen I, collagen II, and fibronectin, (3) that
b1 integrin blocking antibodies fully block binding of
rat MSC to collagen I and collagen II, but only partially
inhibit binding to fibronectin, and (4) that RGD pep-
tides partially block the adhesion of MSC to fibronectin
in vitro and to cartilage lesions ex vivo. Thus, our data
suggest that both RGD- and collagen-binding integrins
are involved in the attachment of MSC to full-thickness
articular cartilage lesions. This model is shown in
Figure 6. Our study is in line with the findings of
Shimaya and co-workers37 that magnesium increased
adhesion of human synovial MSC to collagen-coated
slides in a b1 integrin-dependent fashion in vitro,
underscoring the importance of b1 integrins for bind-
ing of MSC to ECM proteins across species.
The present study has shown that our newly estab-
lished co-isogeneic ex vivo system consisting of MSC
isolated from hPLAP-tg donor F344 rats and wild-
type F344 osteochondral explants is an excellent tool
to study MSC attachment to cartilage lesions. By use
of the marker gene hPLAP, which is ubiquitously and
stably expressed in hPLAP-tg rats and does not influ-
ence MSC behavior,26,27 we were able to reliably and
very efficiently track hPLAP-expressing MSC attached
to the wild-type osteochondral explants by histochem-
ical detection methods and subsequent image analysis.
In our ex vivo explant system, the near-physiological
combination of 1mM MgCl2 with 2.5mM CaCl2 pro-
vided the best results in terms of MSC-covered area
within the cartilage lesion. Interestingly, calcium had
no or even a negative effect on the adhesion of MSC
to defective cartilage. Conversely, adhesion of MSC to
collagen I, collagen II, and fibronectin in vitro was abol-
ished in the presence of 10mM EDTA. These phenom-
ena have already been described earlier38,39 and are
consistent with the notion that integrinsmay be involved
in the MSC attachment. Divalent cations are needed for
activation of integrins and for keeping them in their ac-
tive state.19–21 ETDA chelates divalent cations, resulting
in an inactive state of cell surface integrins.21 Thus, our
data suggest that the attachment of MSC to ECM pro-
teins accessible in full-thickness cartilage defects is an al-
most entirely integrin-mediated process.
Cultured MSC express various integrin subunits
such as a1, a2, a3, a4, a5, a6, a7, a10, aV, aIIb, b1,
b3, b4, and b5.13–15 The expression of these integrin
subunits on MSC was described earlier on mRNA
and protein level. Expression of the subunits a7, a10,
aIIb, and b5 has so far only been analyzed by microar-
ray hybridization.15 Our in vitro cell attachment assays
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FIG. 5. Expression of a2 integrin at MSC attachment sites to bone and cartilage. (A) Expression of collagen I
and collagen II in cryosections of intact osteochondral explants. Immunofluorescence analysis was
performed on cryosections of hPLAP prestained intact osteochondral explants by incubation with polyclonal
antibodies against collagen I and collagen II. Collagen I is found in bone tissue, whereas collagen II is
exclusively located in cartilage tissue of the intact explant. (B) Alcian blue-PAS staining of intact osteochondral
explants and explants with a full-thickness defect. Articular cartilage is stained purple, subchondral bone is
stained magenta, and proteoglycans are stained blue. (C, D) Expression of a2 integrin in osteochondral
explants with full-thickness defects. Co-immunofluorescence analysis was performed on cryosections of
previously hPLAP-stained and quantified osteochondral explants by parallel incubation with an antibody
against a2 integrin (C, D, green), and a polyclonal antibody against collagen I (C, red) and collagen II (D, red).
a2 integrin and collagen I and II are co-expressed in distinct adjacent zones (merge, yellow, arrows). Merging
with bright light (bl) images demonstrated the co-expression of a2 integrin and collagen I at sites where
hPLAP-tg MSC attach to subchondral bone (C, bl merged, arrows). Bright light-merged images after co-staining
of a2 integrin and collagen II revealed co-expressing sites where hPLAP-tg MSC attach to collagen II (D, bl
merged, arrows). (E, F) Expression of a1 and a5 integrin in osteochondral explants with full-thickness defects.
Immunofluorescence analysis was performed on hPLAP-prestained cryosections of osteochondral explants by
incubation with a monoclonal antibody against a1 integrin (E) and a polyclonal anti-a5 integrin antibody (F).
Expression of neither a1 nor a5 integrin could be observed at sites where hPLAP-tg MSC attach to the cartilage
lesion (bl merged, arrows). Scale bar = 50 lm.
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revealed that MSC attach to collagen I, collagen II, and
fibronectin, but not to collagen XXII and COMP. Col-
lagen I is the main ECM protein in bone, collagen II is
the major matrix molecule in cartilage, and fibronectin
is present in high amounts in both tissues. In agree-
ment with the fact that all collagen-binding integrins
(a1b1, a2b1, a10b1, and a11b1) contain the b1-sub-
unit,20 binding of MSC to collagen I and collagen II
in vitro was fully blocked by the monoclonal b1 integ-
rin blocking antibody. Furthermore, immunofluores-
cence analysis on osteochondral explants with
cartilage lesions demonstrated expression of a2 integ-
rin in distinct zones where MSC attach to collagen I
or collagen II in the lesion, whereas no expression of
a1 and a5 integrin could be observed. These distinct
zones are likely to be focal adhesion sites that can de-
velop into focal adhesion plaques, and are known as
first step of integrin signaling.20
The finding that a2b1 integrin may be involved in
MSC attachment to cartilage lesions explains the strong
influence of magnesium and the lacking influence of
calcium in our ex vivo attachment experiments, be-
cause a2 integrin needs the presence of magnesium
rather than calcium to bind to collagens.41,42 In addi-
tion, b1 integrins were also shown to be essential for
MSC attachment and survival in biodegradable poly-
mers.18 In contrast to collagens, fibronectin interacts
with RGD-binding integrins (e.g., a5b1, aVb1, aVb3,
aVb5, and aIIbb3).20 It is interesting to note in this
context that the attachment of MSC to fibronectin
could not be fully inhibited by the b1 integrin blocking
antibody in our experiments, a finding which may in-
dicate that additional RGD-binding b-subunits are in-
volved in the attachment to fibronectin. Because we
were unable to detect expression of a5 integrin in im-
munofluorescence analysis, it is tempting to speculate
that aV integrins may mediate the attachment of
MSC to fibronectin. Clearly, more work needs to be
done to fully characterize all integrins involved in the
attachment of MSC to cartilage lesions.
MSC for cell-based therapies are usually suspended
in saline,7 hyaluronic acid,5,8 or serum6,10 prior to in-
jection. Our study demonstrated that the addition of
serum to the cell suspension provided the best results
in terms of MSC attachment to full-thickness cartilage
lesions, when compared with plasma, bone marrow
plasma, hyaluronic acid, or saline. The difference be-
tween serum and plasma might be explained by the
fact that EDTA was used to prevent blood coagulation
during harvesting of plasma samples. Serum is com-
posed of numerous components, and it is currently un-
known which specific serum proteins are able to
modulate ex vivo and in vivo MSC attachment. Clearly,
more work has to be done to characterize the individ-
ual factors present in serum that improve MSC at-
tachment to cartilage lesions. It is obvious that this
knowledge could be exploited to further refine MSC-
based therapies.
In conclusion, our study demonstrates the crucial
function of b1 integrins for the attachment of MSC
to ECM proteins accessible to binding in full-thickness
cartilage defects. More experimentation is required to
FIG. 6. Model for MSC adhesion to articular cartilage lesions. MSC are able to bind to collagen I in bone and
to collagen II in cartilage in full-thickness cartilage defects (dashed line) via collagen-binding b1 integrins.
In addition, MSC interact via RGD-binding integrins with fibronectin, a major matrix protein present in bone
and cartilage.
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exactly define the nature of the individual a-subunits,
and possibly additional b-subunits involved in the at-
tachment process of MSC to ECM proteins present in
bone and cartilage. A better understanding of the mo-
lecular mechanisms involved in MSC adhesion may
lead to significant improvements in MSC-based thera-
pies for osteochondral defect regeneration.
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